PA

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Perez OA et al. – Current therapies are primarily directed against the formation of these antibodies by suppression of the immune system, and are associated with significant adverse events. As our understanding of the pathophysiology of pemphigus increases, newer therapies have been proposed and evaluated. These novel therapies include intravenous immunoglobulin, plasmapheresis, immunoadsorption, extracorporeal photochemotherapy, biological agents, as well as experimental therapies such as cholinergic receptor agonists, Dsg3 peptides and a p38 mitogen–activated protein kinase inhibitor. Current limitations to the widespread use of these therapies include cost, a lack of consistent data regarding their benefit, limited availability, and the experimental nature of some of the treatments. This review highlights the latest case reports and studies that employ established as well as new therapeutics in a novel way to treat this rare, but serious, disorder.

   

Related Articles

Subcorneal Pustular Dermatosis-Type IgA Pemphigus With Autoantibodies to Desmocollins 1, 2, and 3
Archives of Dermatology, 10/22/09    Relevance Score: 88%

Treatment of pemphigus vulgaris and pemphigus foliaceus
Expert Review of Dermatology, 10/13/09    Relevance Score: 88%

Pemphigus herpetiformis: analysis of the autoantibody profile during the disease course with changes in the clinical phenotype
Clinical and Experimental Dermatology, 11/10/09    Relevance Score: 85%

Demonstration of pemphigus-specific immunofluorescence pattern by direct immunofluorescence of plucked hair
International Journal of Dermatology, 10/28/09    Relevance Score: 85%

Efficacy of Dapsone in the Treatment of Pemphigus and Pemphigoid: Analysis of Current Data
American Journal of Clinical Dermatology, 10/20/09    Relevance Score: 85%

Today in Clinical Pharmacology...keeping you current

U.S. Opioid Risk Management Initiatives
Pain: Clinical Updates (IASP’s clinical newsletter), 11/20/09

Aspirin is associated with reduced cardiovascular and all-cause mortality in type 2 diabetes in a primary prevention setting: The Fremantle Diabetes Study
Diabetes Care, 11/20/09

Recurrence of Hyperprolactinemia after Withdrawal of Dopamine Agonists: Systematic Review and Meta-Analysis
Journal of Clinical Endocrinology and Metabolism, 11/20/09

Today in Dermatology...keeping you current

Use of Oral N-Acetylcysteine for Protection of Melanocytic Nevi against UV-Induced Oxidative Stress: Towards a Novel Paradigm for Melanoma Chemoprevention
Clinical Cancer Research, 11/20/09

BRAF V600E mutation and the tumour suppressor IGFBP7 in atypical genital naevi
British Journal of Dermatology, 11/20/09

Iatrogenic Bullae Following Cupping Therapy
Journal of Alternative and Complementary Medicine, 11/20/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address